-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-03-28
3020-OL:HK:HK-X DBMSCIUSA (HKD)
COMMON STOCK | Other |
Last Closing
USD 1203Change
+8.00 (+0.67)%Market Cap
N/AVolume
105.00Analyst Target
N/AN/A
Verdict
Values as of: 2024-03-28
COMMON STOCK | Other |
Last Closing
USD 1203Change
+8.00 (+0.67)%Market Cap
N/AVolume
105.00Analyst Target
N/AN/A
Verdict
Currency: HKD
Country : Hong Kong
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
1863:HK | China Longevity Group Company .. |
N/A |
USD 1.17B |
8355:HK | I-CONTROL |
N/A |
USD 0.39B |
8343:HK | HongGuang Lighting Holdings Co.. |
N/A |
USD 0.31B |
0648:HK | CHINA RENJ |
N/A |
USD 0.12B |
0177-OL:HK | JIANGSU EXPRESS |
N/A |
N/A |
0240-OL:HK | BUILD KING HOLD |
N/A |
N/A |
0243-OL:HK | QPL INT'L |
N/A |
N/A |
0182-OL:HK | CHINA WINDPOWER |
N/A |
N/A |
0259-OL:HK | YEEBO (INT'L H) |
N/A |
N/A |
0187-OL:HK | JINGCHENG MAC |
N/A |
N/A |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
IHF | iShares U.S. Healthcare P.. | 9.59 % | 0.43 % |
N/A |
USD 0.82B |
TETF | 6.19 % | 0.64 % |
N/A |
N/A | |
WBIL | WBI BullBear Quality 3000.. | 4.55 % | 1.07 % |
N/A |
USD 0.04B |
IAI | iShares U.S. Broker-Deale.. | 4.28 % | 0.42 % |
N/A |
USD 0.49B |
CBUF:XETRA | iShares MSCI World Health.. | 3.51 % | 0.00 % |
N/A |
USD 1.13B |
HDIV | 2.83 % | 0.00 % |
N/A |
N/A | |
SPVU | Invesco S&P 500® Enhance.. | 2.73 % | 0.16 % |
N/A |
USD 0.11B |
UC96:LSE | UBS (Irl) ETF plc - Facto.. | 2.37 % | 0.00 % |
N/A |
USD 0.35B |
UPVL:LSE | UBS (Irl) ETF plc - Facto.. | 2.37 % | 0.00 % |
N/A |
USD 8.21M |
UBUS:F | UBS (Irl) ETF Public Limi.. | 2.35 % | 0.00 % |
N/A |
USD 0.33B |
UBUW:F | UBS (Irl) ETF Public Limi.. | 2.35 % | 0.00 % |
N/A |
USD 0.02B |
UBUS:XETRA | UBS (Irl) ETF plc - Facto.. | 2.35 % | 0.00 % |
N/A |
USD 0.49B |
UBUW:XETRA | UBS (Irl) ETF plc - Facto.. | 2.35 % | 0.00 % |
N/A |
USD 0.05B |
NSGE:CA | NBI Sustainable Global Eq.. | 2.32 % | 0.00 % |
N/A |
CAD 0.53B |
XHS | SPDR® S&P Health Care Se.. | 2.13 % | 0.35 % |
N/A |
USD 0.08B |
FXH | First Trust Health Care A.. | 2.13 % | 0.63 % |
N/A |
USD 1.33B |
SPVM | Invesco S&P 500 Value wit.. | 1.78 % | 0.39 % |
N/A |
USD 0.09B |
RYH | 1.72 % | 0.40 % |
N/A |
N/A | |
HONR | 1.20 % | 0.65 % |
N/A |
N/A | |
VVL:CA | Vanguard Global Value Fac.. | 0.64 % | 0.40 % |
N/A |
CAD 0.35B |
SMD | 0.45 % | 0.10 % |
N/A |
N/A | |
ESGL | ESGL Holdings Limited Ord.. | 0.00 % | 0.40 % |
N/A |
USD 5.46M |
DUSA | 0.00 % | 0.63 % |
N/A |
N/A | |
DRFU:CA | Desjardins RI USA Multifa.. | 0.00 % | 0.57 % |
N/A |
CAD 5.97M |
RYF | 0.00 % | 0.40 % |
N/A |
N/A | |
XXM:CA | 0.00 % | 0.68 % |
N/A |
N/A | |
XMWD:LSE | Xtrackers MSCI World Swap.. | 0.00 % | 0.00 % |
N/A |
USD 4.20B |
IMCG | iShares Morningstar Mid-C.. | 0.00 % | 0.00 % |
N/A |
N/A |
Market Performance vs. Industry/Classification (Other) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 11.49% | 83% | B | 82% | B | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 11.49% | 83% | B | 82% | B | ||
Trailing 12 Months | |||||||
Capital Gain | 31.85% | 92% | A | 89% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 31.85% | 91% | A- | 88% | B+ | ||
Trailing 5 Years | |||||||
Capital Gain | 99.83% | 84% | B | 92% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 99.83% | 84% | B | 91% | A- | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 13.89% | 79% | B- | 79% | B- | ||
Dividend Return | 13.89% | 76% | C+ | 77% | C+ | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 19.67% | 71% | C- | 71% | C- | ||
Risk Adjusted Return | 70.62% | 98% | N/A | 97% | N/A | ||
Market Capitalization | N/A | N/A | N/A | N/A | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
There is nothing we particularly dislike